Market Size of Global Active Pharmaceutical Ingredients CDMO Industry
Study Period | 2019 - 2029 |
Market Size (2024) | USD 118.09 Billion |
Market Size (2029) | USD 178.47 Billion |
CAGR (2024 - 2029) | 8.61 % |
Fastest Growing Market | Asia-Pacific |
Largest Market | Asia-Pacific |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Active Pharmaceutical Ingredients CDMO Market Analysis
The Global Active Pharmaceutical Ingredients CDMO Market size is estimated at USD 118.09 billion in 2024, and is expected to reach USD 178.47 billion by 2029, growing at a CAGR of 8.61% during the forecast period (2024-2029).
Various factors, such as increasing pharmaceutical research and development investment, rising demands for generic drugs, complex manufacturing, and patent expiration, will lead to market growth during the forecast period.
The increase in pharmaceutical research and development (R&D) investment is one of the factors significantly driving the market growth. The rise in pharmaceutical R&D investment is expected to fuel the adoption of active pharmaceutical ingredient (API) contract development and manufacturing organizations (CDMO) to develop APIs. For instance, the report published by the European Federation of Pharmaceutical Industry and Associations in June 2023 highlighted that pharmaceutical companies invested USD 49,112 million in R&D in Europe in 2022. Additionally, the same source reported that the R&D investments were majorly allocated to clinical trials (49.2%), followed by pre-clinical functions (14.7%) and pharmacovigilance (12.9%). Thus, significant investments by pharmaceutical companies are the primary factors expected to boost the market during the forecast period.
In addition, the increasing demand for generic drugs due to the growing burden of chronic diseases contributes significantly to the market growth. Generic drugs are used to treat complicated chronic disorders like cancers, cardiovascular disorders, neurological disorders, and infections. For instance, an article published by the National Institutes of Health in July 2023 mentioned that about 10.5 million people had dementia in 2022, which is expected to increase to 18.7 million in 2050. Moreover, according to 2023 updated data published by the International Diabetes Federation, diabetic patients are expected to reach 643 million and 784 million globally by 2030 and 2045, respectively. Thus, the increase in chronic disease prevalence is anticipated to fuel the demand for generic drugs, further strengthening the market growth of API CDMO during the forecast period.
The market players have adopted various strategies to expand API manufacturing, further boosting market growth. For instance, in December 2022, Novasep invested approximately USD 6.3 million (EUR 6 million) to enhance its Chasse-sur-Rhône facility in France. The investment focused on improving the site's capabilities in handling advanced APIs related to specialized medical fields, including oncology, central nervous system (CNS) disorders, and infectious diseases. Additionally, in May 2022, Piramal Pharma Solutions stated that the company's new active pharmaceutical ingredient (API) plant in Aurora, Ontario, went online and completed its initial production runs. Thus, such initiatives are anticipated to drive the API CDMO market growth during the forecast period.
Hence, increasing R&D investments and rising demand for generic drugs due to the growing burden of chronic diseases among patients are the major factors driving the market growth. However, compliance issues while outsourcing and concerns about data quality and security are expected to affect the market growth of API CDMO during the forecast period.
Active Pharmaceutical Ingredients CDMO Industry Segmentation
As per the scope of this report, an active pharmaceutical ingredient (API) is the part of the drug that produces the intended effects. It is the biologically active component of a drug product, such as a capsule, tablet, injectable, or cream. Traditionally, pharmaceutical companies would produce APIs. However, in recent years, many companies have opted to outsource the production of API, as most companies have realized that the returns on investments have been worthwhile. With the right outsourcing partner, the advantages outweigh the potential risks.
The active pharmaceutical ingredients CDMO market is segmented by molecule type, synthesis, drug type, workflow, application, and geography. By molecule type, the market is segmented into small and large molecules. By synthesis, the market is segmented into biotech and synthetic. By drug type, the market is segmented into innovative and generics. By workflow, the market is segmented into clinical and commercial. The market is segmented by application into cardiology, oncology, ophthalmology, neurology, orthopedic, and other applications. The market is segmented by geography into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. For each segment, the market size is provided in terms of USD value.
By Molecule Type | |
Small Molecule | |
Large Molecule |
By Synthesis | |
Biotech | |
Synthetic |
By Drug Type | |
Innovative | |
Generics |
By Workflow | |
Clinical | |
Commercial |
By Application | |
Cardiology | |
Oncology | |
Ophthalmology | |
Neurology | |
Orthopedic | |
Other Applications |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Active Pharmaceutical Ingredients CDMO Market Size Summary
The API CDMO market is poised for significant growth, driven by increasing investments in pharmaceutical research and development, the rising demand for generic drugs, and the complexities of modern drug manufacturing. The market is expected to expand substantially over the forecast period, with strategic initiatives by key players further propelling its growth. The demand for active pharmaceutical ingredients is bolstered by the growing prevalence of chronic diseases, necessitating the development and production of effective pharmaceuticals. This has led to a surge in the adoption of API CDMO services, as pharmaceutical companies seek to enhance their manufacturing capabilities and meet the evolving needs of the market.
Regionally, Asia-Pacific is anticipated to be a major contributor to the market's expansion, supported by substantial investments in pharmaceutical production and favorable government initiatives. Countries like India are playing a pivotal role, with initiatives such as the Production Linked Incentive scheme boosting API manufacturing. The market landscape is characterized by a mix of established players and emerging companies, all vying to capture market share through strategic expansions, collaborations, and investments. As the industry continues to evolve, the API CDMO market is set to experience robust growth, driven by both demand-side factors and strategic actions by market participants.
Global Active Pharmaceutical Ingredients CDMO Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Pharmaceutical R&D Investment
-
1.2.2 Rising Demand for Generic Drugs
-
1.2.3 Complex Manufacturing
-
1.2.4 Patent Expiration
-
-
1.3 Market Restraints
-
1.3.1 Compliance Issues while Outsourcing
-
1.3.2 Concerns about Data Quality and Security
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Molecule Type
-
2.1.1 Small Molecule
-
2.1.2 Large Molecule
-
-
2.2 By Synthesis
-
2.2.1 Biotech
-
2.2.2 Synthetic
-
-
2.3 By Drug Type
-
2.3.1 Innovative
-
2.3.2 Generics
-
-
2.4 By Workflow
-
2.4.1 Clinical
-
2.4.2 Commercial
-
-
2.5 By Application
-
2.5.1 Cardiology
-
2.5.2 Oncology
-
2.5.3 Ophthalmology
-
2.5.4 Neurology
-
2.5.5 Orthopedic
-
2.5.6 Other Applications
-
-
2.6 Geography
-
2.6.1 North America
-
2.6.1.1 United States
-
2.6.1.2 Canada
-
2.6.1.3 Mexico
-
-
2.6.2 Europe
-
2.6.2.1 Germany
-
2.6.2.2 United Kingdom
-
2.6.2.3 France
-
2.6.2.4 Italy
-
2.6.2.5 Spain
-
2.6.2.6 Rest of Europe
-
-
2.6.3 Asia-Pacific
-
2.6.3.1 China
-
2.6.3.2 Japan
-
2.6.3.3 India
-
2.6.3.4 Australia
-
2.6.3.5 South Korea
-
2.6.3.6 Rest of Asia-Pacific
-
-
2.6.4 Middle East and Africa
-
2.6.4.1 GCC
-
2.6.4.2 South Africa
-
2.6.4.3 Rest of Middle East and Africa
-
-
2.6.5 South America
-
2.6.5.1 Brazil
-
2.6.5.2 Argentina
-
2.6.5.3 Rest of South America
-
-
-
Global Active Pharmaceutical Ingredients CDMO Market Size FAQs
How big is the Global Active Pharmaceutical Ingredients CDMO Market?
The Global Active Pharmaceutical Ingredients CDMO Market size is expected to reach USD 118.09 billion in 2024 and grow at a CAGR of 8.61% to reach USD 178.47 billion by 2029.
What is the current Global Active Pharmaceutical Ingredients CDMO Market size?
In 2024, the Global Active Pharmaceutical Ingredients CDMO Market size is expected to reach USD 118.09 billion.